Market News / Story
Jupiter Neurosciences, Inc. (JUNS) Starts Phase 2a Dosing in Parkinson’s, Reviews Strategic Options
·
Jupiter Neurosciences dosed the first patient in its Phase 2a RESET trial of JOTROL in Parkinson’s and retained Tungsten Advisors to explore asset monetization, partnerships, licensing, or other transactions. RESET targets ~30 patients over 12 weeks with safety and PK as primaries. Material Details #DetailAI Analyst View1First patient dosed in Phase 2a RESETAdvances lead asset into mid-stage testing, a typical stock catalyst for small-cap biopharma.2Trial to enroll ~30…